Literature DB >> 20888048

An estimate of the minimum economic burden of bipolar I and II disorders in the United States: 2009.

Steven C Dilsaver1.   

Abstract

OBJECTIVE: To conduct an analysis yielding estimates of the direct and indirect costs accruing from bipolar I and II disorders in 2009. The last analysis of these costs pertained to 1991.
METHODS: The analysis presented is based on recent epidemiological data, a measure of the increase in the cost of health care services and commodities between 1991 and December 31, 2009, a measure of the increase in the cost of living after partialing out of the costs of health care between 1991 and December 31, 2009 and adjustment for growth in the population of the United States between 1991 and 2009 to calculate the direct and indirect costs of bipolar I and II disorders.
RESULTS: The estimated direct and indirect costs of bipolar I and II disorders in 2009 were 30.7 and 120.3 billion dollars, respectively. The estimated total economic burden imposed by these disorders was 151.0 billion dollars. The increase in costs between 1991 and 2009 was not entirely due to inflation. Bipolar I and II disorders are now estimated to have a combined prevalence exceeding that used in the calculation of costs for 1991 by 1.6154-fold. Direct costs escalated out of proportion (2.2393-fold) to indirect costs (1.6148-fold). LIMITATIONS: The analysis required the acceptance assumptions that likely resulted in a net-underestimation of costs and did not take the entirety of the bipolar spectrum into account.
CONCLUSIONS: The findings have implications for the formulation of public policy. The lifetime prevalences of not only bipolar I and II disorders but also the high prevalence of the entire body of bipolar spectrum disorders, the suffering that they create and the economic burden imposed by them render them worthy of having a high priority in the formulation of plans for the delivery of health care services, planning educational programs for the public and informing policymakers.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 20888048     DOI: 10.1016/j.jad.2010.08.030

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  55 in total

1.  Testing for clinical inertia in medication treatment of bipolar disorder.

Authors:  Dominic Hodgkin; Elizabeth L Merrick; Peggy L O'Brien; Thomas G McGuire; Sue Lee; Thilo Deckersbach; Andrew A Nierenberg
Journal:  J Affect Disord       Date:  2016-06-21       Impact factor: 4.839

2.  Comparison of health services use associated with ziprasidone and olanzapine among schizophrenia and bipolar disorder patients in the USA.

Authors:  Yawen Jiang; Weiyi Ni; Justin J McGinnis
Journal:  Clin Drug Investig       Date:  2014-07       Impact factor: 2.859

3.  Exon Array Biomarkers for the Differential Diagnosis of Schizophrenia and Bipolar Disorder.

Authors:  Marquis Philip Vawter; Robert Philibert; Brandi Rollins; Patricia L Ruppel; Terry W Osborn
Journal:  Mol Neuropsychiatry       Date:  2018-04-10

Review 4.  Diagnosis and treatment of bipolar disorders in adults: a review of the evidence on pharmacologic treatments.

Authors:  Michael W Jann
Journal:  Am Health Drug Benefits       Date:  2014-12

Review 5.  Dopamine Receptor Partial Agonists for the Treatment of Bipolar Disorder.

Authors:  Jean-Michel Azorin; Nicolas Simon
Journal:  Drugs       Date:  2019-10       Impact factor: 9.546

Review 6.  Integrating bipolar disorder management in primary care.

Authors:  Amy M Kilbourne; David E Goodrich; Allison N O'Donnell; Christopher J Miller
Journal:  Curr Psychiatry Rep       Date:  2012-12       Impact factor: 5.285

Review 7.  A Systematic Review and Critical Appraisal of Economic Evaluations of Pharmacological Interventions for People with Bipolar Disorder.

Authors:  Ifigeneia Mavranezouli; Joran Lokkerbol
Journal:  Pharmacoeconomics       Date:  2017-03       Impact factor: 4.981

8.  An Integrated Risk Reduction Intervention can reduce body mass index in individuals being treated for bipolar I disorder: results from a randomized trial.

Authors:  Ellen Frank; Meredith L Wallace; Martica Hall; Brant Hasler; Jessica C Levenson; Carol A Janney; Isabella Soreca; Matthew C Fleming; Joan Buttenfield; Fiona C Ritchey; David J Kupfer
Journal:  Bipolar Disord       Date:  2014-12-12       Impact factor: 6.744

Review 9.  A review of MR spectroscopy studies of pediatric bipolar disorder.

Authors:  D G Kondo; T L Hellem; X-F Shi; Y H Sung; A P Prescot; T S Kim; R S Huber; L N Forrest; P F Renshaw
Journal:  AJNR Am J Neuroradiol       Date:  2014-02-20       Impact factor: 3.825

10.  Gender differences in health-related quality of life in patients with bipolar disorder.

Authors:  Maria Syl D de la Cruz; Zongshan Lai; David E Goodrich; Amy M Kilbourne
Journal:  Arch Womens Ment Health       Date:  2013-04-16       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.